Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hib-DTaP-Hepatitis-B-Poliovirus vaccine - Sanofi

Next Previous
Drug Profile

Hib-DTaP-Hepatitis-B-Poliovirus vaccine - Sanofi

Alternative Names: 6-in-1 paediatric vaccine - Sanofi; DTaP-IPV-HB-PRP-T; DTaP-IPV-Hep B-PRP-T; DTaP-IPV-Hib-HepB vaccine - Sanofi; DTaP2-IPV-Hep B-PRP-T - Sanofi; DTwP-HepB-Hib-IPV vaccine - Sanofi; Hexacima; Hexaxim; Hexyon

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Haemophilus vaccines; Hepatitis B vaccines; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 22 Feb 2019 Sanofi Pasteur completes a phase III trial for Diphtheria/Tetanus/Pertussis/Hepatitis B/Poliomyelitis/Haemophilus infections (In infants, Prevention) in South Africa (IM) (NCT02817451)
  • 30 Apr 2018 Sanofi Pasteur completes a phase I/II trial for Diphtheria/Tetanus/Pertussis/Hepatitis B/Poliomyelitis/Haemophilus infections (In infants, Prevention) in India (IM) (CTRI2016-11-007434)
  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top